RESEARCH-USE BIOSIMILAR ANTIBODY
Bapineuzumab
Monoclonal antibody · IgG1
Bapineuzumab (AAB-001) is a humanized IgG1 monoclonal antibody that binds to the N-terminal region of amyloid beta in a helical conformation. Bapineuzumab induces microglial activation by upregulating CD11B, producing pro-inflammatory cytokines (IL-1β and TNFα), clearing plaques, and reducing insoluble and aggregated Aβ. Bapineuzumab can be used for research on Alzheimer's disease.
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Bapineuzumab (AAB-001) is a humanized IgG1 monoclonal antibody that binds to the N-terminal region of amyloid beta in a helical conformation. Bapineuzumab induces microglial activation by upregulating CD11B, producing pro-inflammatory cytokines (IL-1β and TNFα), clearing plaques, and reducing insoluble and aggregated Aβ. Bapineuzumab can be used for research on Alzheimer's disease.
Bapineuzumab is a recombinant research-use antibody directed against APP.